Vanguard Group
RNAM

Vanguard Group’s Avidity Biosciences RNAM Stock Holding History

Vanguard Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$985M Buy
13,649,250
+429,491
+3% +$27.7M 0.01% 723
2025
Q3 		$576M Buy
13,219,759
+3,971,457
+43% +$161M 0.01% 984
2025
Q2 		$263M Buy
9,248,302
+5,097
+0.1% +$152K ﹤0.01% 1376
2025
Q1 		$273M Sell
9,243,205
-188,706
-2% -$5.88M ﹤0.01% 1325
2024
Q4 		$274M Buy
9,431,911
+205,027
+2% +$8.57M ﹤0.01% 1385
2024
Q3 		$424M Buy
9,226,884
+3,283,202
+55% +$142M 0.01% 1131
2024
Q2 		$243M Buy
5,943,682
+2,098,610
+55% +$60.2M ﹤0.01% 1392
2024
Q1 		$98.1M Sell
3,845,072
-198,107
-5% -$3.1M ﹤0.01% 1877
2023
Q4 		$36.6M Buy
4,043,179
+28,689
+0.7% +$192K ﹤0.01% 2318
2023
Q3 		$25.6M Buy
4,014,490
+47,305
+1% +$408K ﹤0.01% 2451
2023
Q2 		$44M Buy
3,967,185
+485,468
+14% +$6.09M ﹤0.01% 2239
2023
Q1 		$53.4M Buy
3,481,717
+11,091
+0.3% +$244K ﹤0.01% 2145
2022
Q4 		$77M Buy
3,470,626
+772,250
+29% +$11.5M ﹤0.01% 1948
2022
Q3 		$44.1M Buy
2,698,376
+276,254
+11% +$5.28M ﹤0.01% 2243
2022
Q2 		$35.2M Buy
2,422,122
+123,759
+5% +$1.84M ﹤0.01% 2362
2022
Q1 		$42.5M Buy
2,298,363
+294,791
+15% +$5.01M ﹤0.01% 2384
2021
Q4 		$47.6M Buy
2,003,572
+60,959
+3% +$1.46M ﹤0.01% 2381
2021
Q3 		$47.8M Buy
1,942,613
+670,815
+53% +$14.6M ﹤0.01% 2385
2021
Q2 		$31.4M Sell
1,271,798
-11,273
-0.9% -$262K ﹤0.01% 2610
2021
Q1 		$28M Buy
1,283,071
+468,745
+58% +$11.5M ﹤0.01% 2610
2020
Q4 		$20.8M Buy
814,326
+65,055
+9% +$1.9M ﹤0.01% 2614
2020
Q3 		$21.1M Buy
749,271
+729,271
+3,646% +$21.1M ﹤0.01% 2436
2020
Q2 		$565K Buy
+20,000
New +$577K ﹤0.01% 3743

Other funds holding RNAM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Vanguard Group's RNAM Position: Q4 2025 in Review

Vanguard Group increased its Avidity Biosciences (RNAM) stake by 3.2% in Q4 2025, buying an estimated $27.7M and bringing the position to 13,649,250 shares worth $985M. The position accounts for 0.01% of the portfolio, ranked #723.

Vanguard Group first reported a position in RNAM in Q2 2020 and has held it in 23 quarters since. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Vanguard Group held 13,649,250 shares of Avidity Biosciences worth $985M as of Q4 2025.
  • Vanguard Group bought 429,491 Avidity Biosciences shares in Q4 2025, an estimated $27.7M.
  • Avidity Biosciences made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #723 holding.
  • Vanguard Group first reported a position in Avidity Biosciences in Q2 2020 and has held it in 23 quarters since.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.